FIA
IBO

FNY Investment Advisers’s Impact BioMedical IBO Stock Holding History

FNY Investment Advisers’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,600
Closed -$18K – 1040
2024
Q4 		$18K Buy
+12,600
New +$26.1K 0.01% 444

Other funds holding IBO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

FNY Investment Advisers's IBO Position: Q1 2025 in Review

FNY Investment Advisers sold out of Impact BioMedical (IBO) in Q1 2025, closing a stake of 12,600 shares — an estimated $18K sold.

FNY Investment Advisers first reported a position in IBO in Q4 2024 and held it in 1 quarter. The position peaked at $18K in Q4 2024. 16 funds tracked by Wall St. Rank hold IBO as of Q1 2025.

  • FNY Investment Advisers reported no remaining Impact BioMedical position as of Q1 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 12,600 Impact BioMedical shares in Q1 2025, an estimated $18K.
  • FNY Investment Advisers first reported a position in Impact BioMedical in Q4 2024 and held it in 1 quarter.
  • FNY Investment Advisers's Impact BioMedical position peaked at $18K in Q4 2024.
  • 16 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2025.

Based on FNY Investment Advisers's 13F filing for Q1 2025, filed 17 Apr 2025.